Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
The deal marks the first immuno-oncology program for Jazz Pharma. With it, they are trying to become a leading oncology company. Here’s more about their success.
Sunshine Biopharma, Inc announced this week that its novel-formulation mRNA molecules induce cancer cell death in cell cultures.
This week, two studies provided big insights into brain changes and specific genetic sites and risk factors for Alzheimer’s disease. For those and more, continue reading.
Global health officials are monitoring COVID-19 cases with an eye to identifying the emergence of new, potentially more deadly or more infectious variants. Read on for more details.
Pfizer is taking a deeper dive into infectious disease with the acquisition of North Carolina-based ReViral, a biotech focused on developing therapeutics that target respiratory syncytial virus (RSV).
An article in Nature explains that ten genes, upon severe mutation that alters genetic function, are linked to an increased risk of the development of schizophrenia.
The company presented an update on its Phase III LAVENDER study of trofinetide for Rett syndrome at the American Academy of Neurology’s annual meeting in Seattle.
Carver Biosciences is developing next-generation gene editing technology using Cas13. By editing RNA, this method makes it possible to target and then edit or destroy RNA from viruses like SARS-CoV-2.
Retro Biosciences announced on Twitter that it is launching with $180 million in funding. Not much is known about the company, except that it indicates it is focused on the “cellular drives of aging.”
A team of scientists from Mount Sinai was able to uncover specific tumor microenvironment (TME) regulators using a novel functional genomics technology known as Perturb-map.
The data demonstrated that the drug, when given to the patients for more than seven days, offered a protection rate of 100%.
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
PRESS RELEASES
Head-to-Head Study Highlights Rocbrutinib as the World’s First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations
Corporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing Operations